Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eton Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eton Pharmaceuticals's regulatory disclosures and financial reporting.
Eton Pharmaceuticals reported submitting a Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration to expand the indication of KHINDIVI (hydrocortisone) oral solution to younger pediatric patients. The new KHINDIVI formulation showed bioequivalence to ALKINDI SPRINKLE, an FDA-approved hydrocortisone granule formulation.
KHINDIVI is currently approved as replacement therapy for pediatric patients 5 years of age and older with adrenocortical insufficiency and is the only FDA‑approved oral hydrocortisone solution. Management comments that label expansion could potentially occur in the first half of 2027. Eton estimates approximately 10,000 pediatric adrenal insufficiency patients in the U.S. and highlights extensive safety warnings, including risks of adrenal crisis, hyperosmolarity, metabolic acidosis, growth retardation, Cushing’s syndrome, bone density loss, psychiatric effects, ophthalmic and gastrointestinal adverse reactions.
BlackRock, Inc. reports beneficial ownership of 1,882,410 shares of Eton Pharmaceuticals, Inc. common stock, representing 6.9% of the class as of June 30, 2026. These holdings are attributed to certain business units of BlackRock and its subsidiaries.
BlackRock has sole voting power over 1,850,186 shares and sole dispositive power over 1,882,410 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Eton’s outstanding common shares.
Eton Pharmaceuticals, Inc. ten percent owner Opaleye Management Inc., through a separately managed account and Opaleye, L.P., reported selling a total of 28,315 common shares on July 14, 2026 at a weighted average price of $37.5431 per share. After these indirect sales, the accounts held 40,000 and 2,665,000 shares, respectively, with Opaleye Management disclaiming beneficial ownership except for its pecuniary interest. The amendment states Opaleye Management is no longer subject to Section 16 reporting.
Opaleye Management Inc., a more-than-10% holder of Eton Pharmaceuticals, reported open-market sales totaling 28,315 shares of common stock on July 14, 2026 at a weighted average price of $37.5431 per share. The sales consisted of 13,315 shares held in a separately managed account and 15,000 shares held by Opaleye, L.P. Following these transactions, the managed account held 40,000 shares and Opaleye, L.P. held 2,665,000 shares, all reported as indirect holdings. Opaleye Management may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Eton Pharmaceuticals, Inc. President & CEO Sean Brynjelsen reported only equity acquisitions. He exercised employee stock options covering 200000.0000 shares of common stock at an exercise price of 1.3700 on July 14, 2026, and converted 27500.0000 shares from restricted stock units on July 12, 2026. After these derivative exercises, he directly holds 1061194.0000 common shares, with no sales, gifts, or tax-withholding dispositions reported.
Eton Pharmaceuticals, Inc. Chief Business Officer David Krempa exercised 10,000 Restricted Stock Units, converting them into an equal number of shares of common stock. These RSUs were part of a 40,000-unit grant awarded on July 12, 2022 that vests in four equal annual installments beginning July 12, 2023. Following this vesting-related exercise, Krempa holds 37,025 common shares directly.
Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, Inc., reported open-market sales totaling 126,685 shares of common stock from July 2 to July 7, 2026. The trades were executed at weighted average prices around $37–$38 per share.
Shares were sold through Opaleye, L.P. and a separately managed account for which Opaleye Management serves as investment manager or portfolio manager. After these transactions, Opaleye, L.P. held 2,680,000 shares, and the managed account held 53,315 shares. Opaleye Management states it may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Krempa David reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals Chief Business Officer David Krempa received a grant of 10,000 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Eton common stock. These RSUs vest in four equal annual installments starting on June 26, 2027, as long as he remains employed on each vesting date.
Following this award, Krempa directly holds a reported total of 96,829 derivative-based shares tied to Eton common stock. This filing reflects a compensation-related equity grant rather than an open-market purchase or sale.
ETON affiliate disclosed proposed sales of common stock under Section 144 and related issuer transfers, listing multiple grant-related issuances and recent dispositions by James R. Gruber. The filing lists a 25000-share sale on 06/25/2026, a 25000-share sale on 06/23/2026, and a 3,117-share sale on 06/02/2026.
The record also shows issuer-side stock option exercises and ESPU/RSU cash settlements with discrete share counts and dates through 06/26/2026.
ETON submitted a Form 144 filing reporting a proposed sale of 25,000 shares related to a stock option exercise dated 06/25/2026. The filing lists the broker Raymond James & Associates and indicates cash proceeds.
It also discloses prior sales in the past three months: 25,000 shares on 06/23/2026 for $831,674.00 and 3,117 shares on 06/02/2026 for $84,041.00.